{"entity":{"id":"catb-101","kind":"drug","name":"CATB-101","aka":[],"tldr":"CATB-101 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.","summary":"CatenaBio describes CATB-101 in AACR 2026 abstract 6928. The two payloads inhibit topoisomerase I and tubulin. Cell-derived and patient-derived xenografts and non-GLP monkey studies are preclinical evidence; they do not demonstrate efficacy or a safer therapeutic window in patients. The abstract supports development, without a human response or survival readout.","status":"preclinical","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1538-7445.am2026-6928"}],"tags":["evidence:preclinical"],"related":[],"cancers":[],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"TOP1 inhibitor plus tubulin inhibitor","mechanism":"Dual-payload anti-TROP2 antibody-drug conjugate delivering inhibitors of DNA processing and microtubule function.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/catb-101/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}